United States Pharmaceuticals Regulatory Intelligence Report 2022: Governing Authority and Drug Development, Generic Drugs, New Drug Applications (NDA) – GlobeNewswire


| Source: Research and Markets Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) — The “Regulatory Intelligence Report for Pharmaceuticals in the U.S.” report has been added to ResearchAndMarkets.com’s offering.
The current report provides detailed exposure to regulatory requirements for pharmaceuticals marketing and registration in the USA.
This report highlights the current regulations and comprehensive procedure for the registration, renewal, or notification of the pharmaceuticals, along with the information on the timeline and fee required.
The report also focuses on the labeling and advertising regulations for the pharmaceutical and the process for the registration of the product with any specific variation. These regulations would be helpful for the premarketing of the pharmaceutical in the U.S. market.
The goals of this study are to understand the regulations and requirements of companies in the U.S., as well as foreign companies or establishments planning to manufacture, distribute or market their pharmaceuticals in the U.S. This report provides a brief about the related regulations for registration of the establishments and pharmaceuticals.
Report Includes
Key Topics Covered:
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Scope of Report
1.3 Information Sources
1.4 Analyst’s Credentials
1.5 Related Research Reports

Chapter 2 Governing Authority and Drug Development
2.1 Governing Regulatory Authority
2.2 Drug Development
2.2.1 Market Entry of Nonprescription Drug Products Under OTC Monograph
2.2.2 Cder Small Business and Industry Assistance (Cder Sbia)
2.2.3 Application Types
2.2.4 Fda Approval
2.2.5 Drug Development Designations

Chapter 3 Generic Drugs
3.1 Approval Process for Generic Drugs
3.2 Abbreviated New Drug Application (Anda)

Chapter 4 New Drug Application (Nda)
4.1 Guidance Documents for Ndas
4.2 Laws, Regulations, Policies and Procedures
4.2.1 Code of Federal Regulations (Cfr)
4.2.2 CDER’s Manual of Policies and Procedures (Mapps)
4.2.3 Prescription Drug User Fee Act (Pdufa)
4.2.4 Nda Forms and Electronic Submissions
4.2.5 Advisory Committees
4.3 Electronic Regulatory Submissions and Review
4.3.1 Electronic Common Technical Document (Ectd)
4.3.2 Fda Electronic Submissions Gateway (Esg)
4.4 Drug Recalls
4.4.1 Alerting the Public
4.4.2 Weekly Enforcement Report
4.4.3 Determining the Effectiveness of the Recall
For more information about this report visit https://www.researchandmarkets.com/r/2yrqmp


Leave a Reply

Your email address will not be published.